SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
137 hedge funds and large institutions have $1.72B invested in SpringWorks Therapeutics in 2022 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 56 increasing their positions, 41 reducing their positions, and 24 closing their positions.
2,864% more call options, than puts
Call options by funds: $19.1M | Put options by funds: $644K
37% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 41
4.91% more ownership
Funds ownership: 101.38% → 106.29% (+4.9%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
4% less capital invested
Capital invested by funds: $1.8B → $1.72B (-$77.7M)
7% less funds holding
Funds holding: 148 → 137 (-11)
33% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$37.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.8M |
| 3 |
Barclays
London,
United Kingdom
|
+$20.3M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$18.2M |
| 5 |
BlackRock
New York
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$21M |
| 2 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$15.9M |
| 3 |
PF
Phoenix Financial
Givatayim,
Israel
|
-$13.3M |
| 4 |
Morgan Stanley
New York
|
-$9.51M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$6.82M |
SWTX Hedge Fund Activity: Q4 2022 in Review
137 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q4 2022, worth a combined $1.72B — down 4.3% from $1.8B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of SWTX and 16 opened new positions — a net loss of 8 holders — while 41 trimmed existing stakes and 56 added.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $37.7M. The largest seller was Perceptive Advisors, cutting an estimated $21M.
- 137 institutional investors held SpringWorks Therapeutics (SWTX) as of Q4 2022, down from 148 in Q3 2022.
- Funds reported $1.72B of SpringWorks Therapeutics stock for Q4 2022, down 4.3% quarter-over-quarter.
- 16 funds opened new SpringWorks Therapeutics positions in Q4 2022 and 24 closed out, a net change of -8 holders.
- The largest SpringWorks Therapeutics buyer in Q4 2022 was Baker Bros. Advisors, an estimated $37.7M added.
- The largest SpringWorks Therapeutics seller in Q4 2022 was Perceptive Advisors, an estimated $21M sold.
Based on aggregated 13F filings for Q4 2022.